Le 17-butyrate d'hydrocortisone (Locoid), un trentenaire toujours innovateur.

Pierard, Gérald

Download

Article (Scientific journals)

Le 17-butyrate d'hydrocortisone (Locoid), un trentenaire toujours innovateur.

Pierard, Gérald

2006 • In Revue Médicale de Liège, 61 (2), p. 128-30

Peer reviewed

Permalink
https://hdl.handle.net/2268/6071

PubMed
16566122

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

17-BUTYRATE.pdf

Publisher postprint (441.52 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Dermatologic Agents/chemistry/pharmacology; Humans; Hydrocortisone/analogs & derivatives/chemistry/pharmacology; Molecular Structure

Abstract :

[en] Since half a century, dermocorticoids represent worthy compounds in dermatological therapy. About thirty years ago, hydrocortisone 17-butyrate was introduced on the Belgian market. This compound combines good efficiency and reduced risk of side effects. Its topical formulations have been enriched over time. The original Locoid lipocream and Locoid Crelo presentations confer remarkable qualities to the product. We report a synopsis of clinical and translational studies devoted to this unique dermocorticoid.

Disciplines :

Dermatology

Author, co-author :

Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

French

Title :

Le 17-butyrate d'hydrocortisone (Locoid), un trentenaire toujours innovateur.

Alternative titles :

[en] Hydrocortisone 17-butyrate (Locoid), a thirty-year ongoing innovative drug

Publication date :

2006

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

128-30

Peer reviewed :

Peer reviewed

Available on ORBi :

since 11 February 2009

Statistics

Number of views

474 (3 by ULiège)

Number of downloads

392 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Piérard GE, Lapière ChM.- Les corticoïdes à usage externe. Trente années d'utilisation et perspectives d'avenir. Rev Med Liège, 1984, 34, 156-159
Murray JR.- The history of corticosteroids. Acta Derm Venereol 1989, 69, S4-S6
Piérard GE.- Iatrogenic alterations of the biomechanical properties of human skin. Br J Dermatol, 1978, 98, 113-114
Piérard GE, Piérard-Franchimont C, Ben Mosbah T, et al.- Adverse effects of topical corticosteroids. Acta Derm Venereol, 1989, 69, S26-S30
Radoja N, Komine M, Jho SH, et al.- Novel mechanism of steroid action in skin through glucocorticoid receptor monomers. Moll Cell Biol, 2000, 20, 4328-4339
Lange K, Kleuser B, Gysler A, et al.- Cutaneous inflammation and proliferation in vitro: differential effects and mode of action to topical glucocorticoids. Skin Pharmacol Appl Skin Physiol, 2000, 13, 93-103
Hein R, Korting HC, Mehring T.- Differential effect of medium potent nonhalogenated double-ester-type and conventional glucorticoids on proliferation and chemotaxis of fibroblasts in vitro. Skin Pharmacol, 1994, 7, 300-306
Piérard GE, Piérard-Franchimont C.- Les corticoïdes topiques. Rev Med Liège, 1996, 51, 145-146
Lapière ChM, Piérard GE. Corticothérapie locale. Topische corticotherapie. Publ. Brocades Belga, Bruxelles 1976, pp 1-200
Charman C, Williams H.- The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol, 2003, 21, 193-200
Piérard GE, Piérard-Franchimont C.- Skin immune dowregulators: from bench to bedside. Curr Top Pharmacol, 2003, 7, 109-116
Pfeilschifter J, Mühl H.- Immunopharmacology: anti-inflammatory therapy targeting transcription factors. Eur J Pharmacol, 1999, 375, 237-245
Falkenstein H, Tillmann HC, Christ M, et al.- Multiple actions of steroid hormones a focus on rapid, nongenomic effects. Pharmacol Rev, 2000, 52, 513-556
Adcock IM, Caramori G.- Cross-talk between proinflammatory transcription factors and glucocorticoïds. Immunol Cell Biol, 2001, 79, 376-384
Croxtall JD, Van Hal PT, Choudhury Q, et al.- Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol, 2002, 135, 511-519
De Bosscher K, Vanden Berghe W, Haegeman G.- The interplay between the glucocorticoid receptor and nuclear factor-kappa B or activator protein-1: molecular mechanisms for gene repression. Endocr Rev, 2003, 24, 488-522
Hammer S, Sauer B, Spika I, et al.- Glucocorticoids mediate differential antiapoptotic effects in human fibroblasts and keratinocytes via sphingosine-1-phosphate formation. J Cell Biochem, 2004, 91, 840-851.
Schäfer-Korting M, Kleuser B, Ahmed M, et al.- Glucorticoids for human skin: new aspects of the mechanism of action. Skin Pharmacol Physiol, 2005, 18, 103-114
Surber C, Smith EW.- The mystical effects of dermatological vehicles. Dermatology, 2005, 210, 157-168
Feldman SR, Housman TS.- Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol, 2003, 4, 221-224
Frosch PJ, Reckers R, Wendt H.- The corticoid stratum corneum assay. A new bioassay to evaluate the risk of topical corticosteroids. Arch Dermatol Res, 1981, 270, 252
Wendt H, Frosch PJ.- Clinico-pharniacological models for the assay of topical corticoids. Karger, Basel, 1982, pp 1-61
Piérard GE, Piérard-Franchimont C.- Squamometry as an aid for rating severity of target lesions in atopic dermatitis. Giorn Int Dermatol Ped, 1994, 6, 125-128
Letawe C, Piérard-Franchimont C, Piérard E.- Squamometry in rating the efficacy of topical corticosteroids in atopic dermatitis. Eur J Clin Pharmacol, 1996, 51, 253-258
Piérard-Franchimont C, Willemaers V, Fraiture AL, Piérard GE.- Squamometry in seborrheic dermatitis. Int J Dermatol, 1999, 38, 712-715
Schackert HK, Korting HC, Schafer-Korting M.- Qualitative and quantitative assessment of the benefit-risk ratio of medium potency topical corticosteroids in vitro and in vivo. Bio-Drugs, 2000, 13, 267-277
Piérard-Franchimont C, Kort R, Benzarti H, et al.- Topical corticosteroid formulations and water balance in the stratum corneum. J Dermatol Treat, 1995, 6, 107-111
Marks R.- How to measure the effects of emollients. J Dermatol Treat, 1997, 8, S15-S18
Korting HC, Kerscher M, Vieluf D, et al.- Commercial glucocorticoid formulations and skin dryness. Could it be caused by the vehicle? Ann Dermatol Venereol, 1991, 71, 261-263
De Cuyper C, Degreef HJ, de la Brassinne M, et al.- A randomized, single-blind study to compare hydrocortisone 17-butyrate 0.1% emulsion versus betamethasone 17-21 dipropionate 0.05% lotion in the treatment of patients suffering from psoriasis of the scalp. J Eur Acad Dermatol Venereol, 1995, 5, S104-S105
Piérard GE, Lachapelle JM, Frentz G, et al.- Hydrocortisone 17-butyrate topical emulsion (Locoid Crelo®) in psoriasis. J Eur Acad Dermatol Venereol, 1996, 6, 11-14
Gip L.- Hydrocortisone 17-butyrate (Locoid) fatty cream and betamethasone 17-valerate (Celestone valerate) 0.1% cream in the treatment of patients suffering from psoriasis. Curr Ther Res, 1983, 34, 813-817
Krook G.- A comparative trial of Locoid 0.1% fatty cream and betnovate 0.1% cream in patients suffering from psoriasis. Curr Ther Res, 1983, 33, 57-62
Rajka G, Verjans HL.- Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream versus desonide (Apolar) 0.1% ointment in the treatment of patients suffering from atopic dermatitis. J Int Med Res, 1986, 14, 85-90
Gip L, Verjans HL.- Hydrocortisone 17-butyrate 0.1% lipocream versus betamethasone 17-valerate 0.1% cream in the treatment of patients with dry severe chronic eczema. Curr Ther Res, 1987, 41, 258-264
Guillet G, Nougue J.- Etude comparative en double aveugle de deux dermatocorticoïdes dans l'eczéma aigu ou chronique: 17-butyrate d'hydrocortisone crème épaisse versus dipropionate de bétaméthasone pommade. CR Ther Pharmacol Clin, 1989, 7, 10-17
Koppmans B, Lasthein Anderson B, Mork NJ, et al.- Multicentre randomized double-blind study of Locid lipocream fatty cream twice daily versus Locoid lipocream one daily and Locobase once daily. J Dermatol Treat, 1995, 6, 103-106